Autori: Oucheva Radka
| Naslov | Pre-treated CML Patients in chronic phase (CP) not achieving at least a major cytogenetic remission (MCyR) after imatinib high dose (HD) induction (800 mg/day, 6 months) are at high risk of progression after dose reduction - Sub-analyses from the CELSG phase III "ISTAHIT" trial (Meeting Abstract) |
| Autori | Petzer Andreas L Fong Dominic Lion Thomas Dyagil Irina Masliak Zvenyslava Bogdanovic Andrija D Griskevicius Laimonas Lejniece Sandra Goranov Stefan Gercheva Liana Stojanovic Aleksandar Peytchev Dontcho Tzvetkov Nikolay Griniute Rasa Oucheva Radka Grubinger T Kwakkelstein Marthin Rancati Francesca Gastl Guenther A Wolf Dominik |
| Info | ONKOLOGIE, (2011), vol. 34 br. , Suppl. 6, str. 264-264 |
| Ispravka | ISI/Web of Science Elečas Rang časopisa Citati: ISI/Web of Science |
| Naslov | High-dose imatinib improves cytogenetic and molecular remissions in patients with pretreated Philadelphia-positive, BCR-ABL-positive chronic phase chronic myeloid leukemia: first results from the randomized CELSG phase III CML 11 "ISTAHIT" study (Article) |
| Autori | Petzer Andreas L Wolf Dominik Fong Dominic Lion Thomas Dyagil Irina Masliak Zvenyslava Bogdanovic Andrija D Griskevicius Laimonas Lejniece Sandra Goranov Stefan Gercheva Liana Stojanovic Aleksandar Peytchev Dontcho Tzvetkov Nikolay Griniute Rasa Oucheva Radka Ulmer Hanno Kwakkelstein Marthin Rancati Francesca Gastl Guenther A |
| Info | HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, (2010), vol. 95 br. 6, str. 908-913 |
| Projekat | Novartis |
| Ispravka | ISI/Web of Science Članak Elečas Rang časopisa Citati: ISI/Web of Science Scopus |
